Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Income from Continuing Operations: 2013-2025

Historic Income from Continuing Operations for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $8.8 million.

  • Fortress Biotech's Income from Continuing Operations rose 133.03% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.2 million, marking a year-over-year increase of 36.67%. This contributed to the annual value of -$120.9 million for FY2024, which is 21.60% up from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Income from Continuing Operations is $8.8 million, which was up 124.62% from -$35.9 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Income from Continuing Operations peaked at $8.8 million during Q3 2025, and registered a low of -$62.4 million during Q4 2021.
  • Its 3-year average for Income from Continuing Operations is -$28.3 million, with a median of -$27.2 million in 2024.
  • As far as peak fluctuations go, Fortress Biotech's Income from Continuing Operations plummeted by 159.68% in 2021, and later spiked by 133.03% in 2025.
  • Quarterly analysis of 5 years shows Fortress Biotech's Income from Continuing Operations stood at -$62.4 million in 2021, then climbed by 7.88% to -$57.4 million in 2022, then soared by 49.54% to -$29.0 million in 2023, then rose by 9.21% to -$26.3 million in 2024, then surged by 133.03% to $8.8 million in 2025.
  • Its Income from Continuing Operations stands at $8.8 million for Q3 2025, versus -$35.9 million for Q2 2025 and -$21.8 million for Q1 2025.